Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
  • Patent number: 10344090
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 9, 2019
    Assignees: Shanghai Hangrui Pharmaceutical Co., Ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Jijun Yuan, Xiangdong Qu, Jufang Lin, Xin Ye, Guoqing Cao, Weikang Tao, Lianshan Zhang, Lei Zhang, Li Yang
  • Patent number: 10344332
    Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: July 9, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Purvesh Khatri, Timothy E. Sweeney
  • Patent number: 10336831
    Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 2, 2019
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventor: Charles P. Theuer
  • Patent number: 10336824
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 2, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Patent number: 10336827
    Abstract: Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin ?V antibodies, anti-integrin ?1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 2, 2019
    Assignee: Wayne State University
    Inventor: Ghassan M. Saed
  • Patent number: 10337070
    Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 2, 2019
    Assignee: CardioForecast Ltd.
    Inventors: Kenneth S. Kornman, Lynn Doucette-Stamm, Gordon W. Duff
  • Patent number: 10328116
    Abstract: The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a ?-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 25, 2019
    Assignee: BIG DNA LTD
    Inventors: John Bernard March, Ewan McIntosh Clark
  • Patent number: 10329354
    Abstract: Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 25, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • Patent number: 10328124
    Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 25, 2019
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
  • Patent number: 10329358
    Abstract: The present invention provides an antibody having an activity to specifically bind to human membrane-anchored form ADAM28 at an epitope in a region of the 524th-659th amino acids in the amino acid sequence shown in SEQ ID NO: 2. In addition, the present invention provides a drug delivery vehicle for delivering a drug to a cell or tissue that expresses human membrane-anchored form ADAM28, which contains the antibody.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 25, 2019
    Assignees: GeneFrontier Corporation, KEIO UNIVERSITY
    Inventors: Akira Miyakoshi, Kanehisa Kojoh, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada
  • Patent number: 10329620
    Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 25, 2019
    Assignee: CardioForecast Ltd.
    Inventors: Kenneth S. Kornman, Lynn Doucette-Stamm, Gordon W. Duff
  • Patent number: 10329348
    Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: June 25, 2019
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
  • Patent number: 10323081
    Abstract: Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 18, 2019
    Assignee: GENMAG A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T. J. Van Den Bremer
  • Patent number: 10322184
    Abstract: A therapeutic emulsion is provided comprising a perfluorocarbon emulsion and a therapeutic agent, such as tobramycin. Methods of making and using the emulsion are provided. A method of treating a lung infection is provided.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: June 18, 2019
    Assignees: Carnegie Mellon University, The Regents of the University of Michigan
    Inventors: Ryan A. Orizondo, Mario L. Fabiilli, Keith E. Cook
  • Patent number: 10323095
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland Newman, Steve Granger, Michael Lyman, Dragan Grabulovski, Richard Woods, Michela Silacci, Wenjuan Zha, Isabella Attinger-Toller
  • Patent number: 10316073
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 11, 2019
    Assignees: argenx BVBA, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 10316105
    Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. In certain embodiments, pairs of activating Tie-2 antibodies showed an additive effect on the treatment of influenza infection when combined with anti-influenza HA. In other embodiments, prophylactic administration pairs of activating Tie2 antibodies delayed death and improved survival in a lethal model of E. coli intoxication (sepsis) over isotype/untreated controls.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gavin Thurston
  • Patent number: 10316103
    Abstract: The present invention is related to the anti-Uroplakin III antibodies, kits, cocktails, and use of anti-Uroplakin III antibodies for detection of cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 11, 2019
    Assignee: Biocare Medical, LLC
    Inventors: Weimin Qi, David Tacha
  • Patent number: 10287627
    Abstract: The invention provides compositions and methods for rapid assembly of one or more assembled polynucleotides from a plurality of component polynucleotides, as well as methods of designing polynucleotide primer and linker sets useful in the assembly methods of the invention.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 14, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ryan T. Gill, Ramsey Zeitoun, Andrew Garst
  • Patent number: 10287360
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 14, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université d' Aix-Marseille, Centre National de la Recherche Scientifique (CNRS), CISBIO Bioassays, Institut Jean Paoli & Irene Calmettes
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Patent number: 10287341
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 14, 2019
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 10287355
    Abstract: Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a second antagonist for an integrin receptor. In some embodiments, the methods include enhancing survival of transplanted tissue in a subject. Aspects of the invention further include compositions, e.g., pharmaceutical compositions and kits that find use in methods of the invention.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 14, 2019
    Assignee: The Regents of the University of California
    Inventor: Lu Chen
  • Patent number: 10280436
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: May 7, 2019
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Patent number: 10280222
    Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: May 7, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nicolas Schneider
  • Patent number: 10280215
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: May 7, 2019
    Assignee: Seoul National University R&DB FOUNDATION
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • Patent number: 10273307
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 30, 2019
    Assignees: Biocerox Products B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Patent number: 10266589
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 23, 2019
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Patent number: 10265379
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 23, 2019
    Inventor: Annabelle Rodriguez Oquendo
  • Patent number: 10259874
    Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against TIM-3 and CD3.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 16, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Yun Pei Sharon Goh
  • Patent number: 10253106
    Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 9, 2019
    Assignee: Eisai, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 10254286
    Abstract: Methods are provided for detecting 5T4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4-positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4-positive metastatic cancer or early stage 5T4-positive cancer.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: April 9, 2019
    Assignees: Pfizer Inc., Epic Sciences, Inc.
    Inventors: Steven Pirie-Shepherd, Hans-Peter Gerber, Dena Marrinucci, Eric Tucker
  • Patent number: 10246484
    Abstract: A method is provided for purifying a recombinant protein from a mixture comprising the recombinant protein and related proteins, comprising the steps of: A. using a first equilibrating buffer in a first conductivity and pH to make the recombinant protein bind to an ion exchange medium; B. using a second equilibration buffer in a second conductivity and pH to continually equilibrate the ion exchange medium bound to the protein; C. using a washing liquid in a third conductivity and a gradually increasing pH to wash the ion-exchange medium, and eluting the first category-related proteins; D. using a first eluent in a fourth conductivity and pH to elute the ion exchange medium, and eluting the target recombinant protein; and E. using a second eluent in a fifth conductivity and pH to continually elute the ion exchange medium, and eluting the second category-related proteins.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: April 2, 2019
    Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Hui Hu, Yunbin Zhu, Meiling Zang
  • Patent number: 10250704
    Abstract: A downtime registration service is discussed herein that enables client systems that rely on electronic record management systems to continue generating records during a downtime event for the electronic record management system without relying on a workaround that requires temporary identifiers or reentry of data. The downtime registration system improves the efficiency and accuracy of electronic systems because workarounds that involve using temporary identifiers, or reentering data collected during the downtime, increase the amount of work done and the chance for errors to be introduced into the records. The client systems are in communication with an outside facility providing advanced services, which track the records generated during normal operation (i.e., not downtime) so that new records created during downtime properly reuse existing record identifiers or assign new identifiers that correspond to the clients' record keeping policies.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 2, 2019
    Assignee: EXPERIAN HEALTH, INC.
    Inventors: Kassandra Marie Kurth, Edmond Chase Pilkington, Abby Curtis
  • Patent number: 10247722
    Abstract: Today, despite current advances in combinatorial therapies such as surgery, radiotherapy and chemotherapy, aggressive cancers remain fatal. Cancer stem-like cells (CSCs) may account for chemotherapy resistance and thus represent a promising therapeutic target. In this context, the present inventors identified essential intracellular pathways favoring the self-renewal and survival of CSCs. More precisely, the present inventors showed that the cytokine co-receptor GP130 acts as a co-receptor for Apelin/APJ signaling and that the interaction of Apelin with APJ/GP130 activates a dual signaling pathway involving the Akt/mTOR and STAT3 transcription factor, thereby promoting CSCs survival and self-renewal. They therefore propose to block these pathways in order to treat patients suffering from tumors containing CSCs, such as glioblastomas. In another aspect, the invention relates to the use of the Apelin expression level for evaluating the survival probability of a subject suffering from glioblastoma.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 2, 2019
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Julie Gavard, Eva-Maria Galan-Moya
  • Patent number: 10246507
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 2, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • Patent number: 10239952
    Abstract: Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-?) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc*(NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 26, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: David Scheinberg, Jingyi Xiang, Tao Dao, Su Yan, Cheng Liu
  • Patent number: 10233256
    Abstract: An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: March 19, 2019
    Assignee: THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
    Inventors: Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
  • Patent number: 10233243
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 19, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 10232039
    Abstract: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 19, 2019
    Assignee: Duke University
    Inventors: Paul W. Noble, Dianhua Jiang
  • Patent number: 10233251
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 19, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 10233240
    Abstract: Provided are methods of treating fibrotic conditions in a subject by the identification of specific subsets of fibrogenic myofibroblasts, such as portal fibroblasts expressing mesothelin, and diagnostic methods useful for determining fibrosis, and the prognosis of fibrosis.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: March 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Tatiana Kisseleva, David Brenner
  • Patent number: 10233244
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 19, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Patent number: 10227413
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 12, 2019
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
  • Patent number: 10227334
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Patent number: 10208122
    Abstract: Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 19, 2019
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Patent number: 10208108
    Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a combination of three isolated monoclonal antibodies or any antigen-binding fragment thereof which bind ricin toxin and neutralize its toxic effects, and a pharmaceutically acceptable carrier, excipient or diluent. The invention also provides a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 19, 2019
    Assignee: THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
    Inventors: Ohad Mazor, Ronit Rosenfeld, Arie Ordentlich, Tal Noy-Porat
  • Patent number: 10208096
    Abstract: According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 19, 2019
    Assignee: University of Yamanashi
    Inventors: Tomoyuki Sasaki, Toshiaki Shirai, Katsue Inoue
  • Patent number: 10202452
    Abstract: The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: February 12, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Philip H Tan, Sateesh K Natarajan, Catherine J McMahan
  • Patent number: 10202374
    Abstract: The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R? are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-? (PI3K-?) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: February 12, 2019
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Ram Asrey Vishwakarma, Sandip Bibishan Bharate, Shashi Bhushan, Rammohan Rao Yadav, Santosh Kumar Guru, Prashant Joshi
  • Patent number: 10196458
    Abstract: The present disclosure provides antibodies that specifically bind to circulating and receptor-bound IgE and inhibit IgE-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 5, 2019
    Assignees: The Regents of the University of California, Sixal, Inc.
    Inventors: Ke Zhang, Andrew Saxon